Highest-materiality recent filing
Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29
R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026
Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.
Climb Bio raises $110M in private placement of common stock and pre-funded warrants
Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.
Climb Bio SVP Finance to depart April 30; CFO adds principal accounting officer role
Cindy Driscoll, SVP Finance and principal accounting officer, to separate from Climb Bio effective April 30, 2026, by mutual agreement.
Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026
Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028
First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).
Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA
Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.
Climb Bio exchanges 20.44M shares for pre-funded warrants; RA Capital voting capped at 33%
Exchanged 20,440,000 shares for pre-funded warrants with $0.0001 exercise price via Section 3(a)(9) exemption.
Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials
Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.
Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control
Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.
Climb Bio appoints Susan Altschuller as CFO, grants 600,000 stock options
Appointed Susan Altschuller, Ph.D., MBA, as CFO and Treasurer effective Oct 1, 2025; previously CFO at Cerevel and ImmunoGen.
In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.
Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO
Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.
Climb Bio appoints Cindy Driscoll as Principal Financial Officer; Emily Pimblett resigns
Appointed Cindy Driscoll as SVP Finance, principal financial officer and principal accounting officer effective June 17, 2025.
Climb Bio shareholders elect two directors, ratify PwC as auditor for FY2025
Judith Dunn, Ph.D. elected with 36,827,909 votes for, 6,615,228 withheld, 10,126,633 broker non-votes.
COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO
Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.
The Board of Directors (the “Board”) of Climb Bio, Inc. (the “Company”) appointed Cindy Driscoll as Senior Vice President, Finance of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective as of June 17, 2025
On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025
On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.
Max materiality 0.80 · Median 0.62 · Most common event other_material